CCJ vs. GSK
CCJ (Cameco Corporation) and GSK (GlaxoSmithKline plc) are both stocks. CCJ operates in Uranium (Energy), while GSK operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, CCJ returned 25.85%/yr vs 4.64%/yr for GSK. At a 0.17 correlation, their price movements are largely independent.
Performance
CCJ vs. GSK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CCJ achieves a 15.25% return, which is significantly higher than GSK's 4.91% return. Over the past 10 years, CCJ has outperformed GSK with an annualized return of 25.85%, while GSK has yielded a comparatively lower 4.64% annualized return.
CCJ
- 1D
- 1.93%
- 1M
- -9.69%
- YTD
- 15.25%
- 6M
- 16.00%
- 1Y
- 74.85%
- 3Y*
- 51.07%
- 5Y*
- 37.97%
- 10Y*
- 25.85%
GSK
- 1D
- -1.71%
- 1M
- 1.25%
- YTD
- 4.91%
- 6M
- 6.15%
- 1Y
- 27.36%
- 3Y*
- 17.87%
- 5Y*
- 4.68%
- 10Y*
- 4.64%
CCJ vs. GSK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CCJ Cameco Corporation | 15.25% | 78.38% | 19.47% | 90.49% | 4.35% | 63.19% | 51.47% | -21.08% | 23.58% | -8.20% |
GSK GlaxoSmithKline plc | 4.91% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
Correlation
The correlation between CCJ and GSK is -0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.03 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.03 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.09 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.12 |
Correlation (All Time) Calculated using the full available price history since Mar 15, 1996 | 0.17 |
The correlation between CCJ and GSK shifts across timeframes, from -0.03 (1 year) to 0.17 (all time), reflecting how their relationship changes across market environments.
Fundamentals
CCJ:
$45.93B
GSK:
$103.15B
CCJ:
$1.49
GSK:
$2.85
CCJ:
70.56
GSK:
17.78
CCJ:
0.59
GSK:
1.19
CCJ:
12.97
GSK:
3.16
CCJ:
6.49
GSK:
4.38
CCJ:
$3.54B
GSK:
$32.78B
CCJ:
$1.04B
GSK:
$23.87B
CCJ:
$996.66M
GSK:
$11.30B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CCJ vs. GSK — Risk / Return Rank
CCJ
GSK
CCJ vs. GSK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Cameco Corporation (CCJ) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CCJ | GSK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.33 | ||
| Sortino ratioReturn per unit of downside risk | +0.54 | ||
| Omega ratioGain probability vs. loss probability | 1.25 | 1.19 | +0.06 |
| Calmar ratioReturn relative to maximum drawdown | 2.93 | 1.48 | +1.45 |
| Martin ratioReturn relative to average drawdown | 6.51 | 3.38 | +3.12 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CCJ | GSK | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.35 | 1.02 | +0.33 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.77 | 0.19 | +0.58 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.56 | 0.20 | +0.35 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.23 | 0.32 | -0.09 |
Drawdowns
CCJ vs. GSK - Drawdown Comparison
The maximum CCJ drawdown since its inception was -87.53%, which is greater than GSK's maximum drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for CCJ and GSK.
Loading charts...
Drawdown Indicators
| CCJ | GSK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.53% | -55.70% | -31.83% |
Max Drawdown (1Y)Largest decline over 1 year | -25.69% | -18.63% | -7.06% |
Max Drawdown (3Y)Largest decline over 3 years | -40.01% | -28.46% | -11.55% |
Max Drawdown (5Y)Largest decline over 5 years | -40.01% | -50.10% | +10.09% |
Max Drawdown (10Y)Largest decline over 10 years | -57.22% | -50.10% | -7.12% |
Current DrawdownCurrent decline from peak | -21.37% | -15.91% | -5.46% |
Average DrawdownAverage peak-to-trough decline | -46.09% | -18.87% | -27.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.54% | 8.11% | +3.43% |
Volatility
CCJ vs. GSK - Volatility Comparison
Cameco Corporation (CCJ) has a higher volatility of 15.98% compared to GlaxoSmithKline plc (GSK) at 6.42%. This indicates that CCJ's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CCJ | GSK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.98% | 6.42% | +9.56% |
Volatility (6M)Calculated over the trailing 6-month period | 39.04% | 18.51% | +20.53% |
Volatility (1Y)Calculated over the trailing 1-year period | 55.87% | 26.94% | +28.93% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 49.87% | 25.06% | +24.81% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.69% | 22.89% | +23.80% |
Dividends
CCJ vs. GSK - Dividend Comparison
CCJ's dividend yield for the trailing twelve months is around 0.16%, less than GSK's 3.41% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CCJ Cameco Corporation | 0.16% | 0.19% | 0.22% | 0.20% | 0.39% | 0.29% | 0.46% | 0.67% | 0.53% | 4.33% | 3.82% | 3.24% |
GSK GlaxoSmithKline plc | 3.41% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
Financials
CCJ vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Cameco Corporation and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CCJ vs. GSK - Profitability Comparison
CCJ - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cameco Corporation reported a gross profit of 291.00M and revenue of 847.55M. Therefore, the gross margin over that period was 34.3%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
CCJ - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cameco Corporation reported an operating income of 154.28M and revenue of 847.55M, resulting in an operating margin of 18.2%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
CCJ - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cameco Corporation reported a net income of 131.09M and revenue of 847.55M, resulting in a net margin of 15.5%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
Frequently Asked Questions
CCJ and GSK have a correlation of -0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CCJ has higher volatility (15.98%) compared to GSK (6.42%). In terms of maximum drawdown, CCJ dropped -87.53% vs GSK's -55.70%.
CCJ currently has the higher Sharpe Ratio (1.35 vs 1.02), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CCJ and GSK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer